Optimizing blinatumomab treatment for patients with ALL

Blinatumomab, a bispecific T-cell engager targeting CD19 and CD3, has become an important part of the evolving treatment landscape for B-cell acute lymphoblastic leukemia (B-ALL).¹ Its use has expanded across different ALL disease settings, including relapsed/refractory disease, measurable residual disease (MRD), and first-line treatment.^1,2 As blinatumomab is incorporated at different stages of therapy, several questions remain regarding how best to use it in clinical practice  including when to introduce it, how many treatment cycles to administer, and the appropriate duration of treatment.¹ Additionally, growing interest in reducing exposure to chemotherapy is prompting further consideration of how blinatumomab may be incorporated into reduced-chemotherapy and chemotherapy-free treatment approaches.^3,4 

The ALL Hub was pleased to speak with André Baruchel, Sabina Chiaretti, and Elias Jabbour to gain their expert insights on optimizing blinatumomab use in B-ALL, including patient selection, treatment duration, and the use of reduced-chemotherapy and chemotherapy-free approaches.  

This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.